I-MAK Comments to the U.S. Department of Health and Human Services on the Trump Administration “Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs”

[Initiative for Medicines, Access & Knowledge]… I-MAK’s years of research and successful legal challenges show that all too often, drug manufacturers hold unmerited patents on old science. This enables a few manufacturers to corner the market on entire diseases, artificially inflating the price of treatment, and blocking access to affordable generic drugs for decades. We believe America is facing two inter-related challenges: a drug pricing crisis and a patent system that is excessively tilted in favor of pharmaceutical manufacturers over patients.